Drug Profile
Foslinanib - TaiRx
Alternative Names: CVM-1118; TRX-818Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator TaiRx
- Class Antineoplastics; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer; Neuroendocrine tumours
- No development reported Cancer; Lymphoma; Solid tumours
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO, Controlled release)
- 02 Jun 2023 Adverse events, pharmacokinetic and efficacy data from a phase II trial in Neuroendocrine-tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 10 Jan 2023 TaiRx terminates phase II trial in liver cancer (Late-stage disease, Combination therapy, First-line therapy) in USA and Taiwan (PO) due to slow enrollment (NCT03582618)